EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comprehensive assessment reveals numerous clinical and neurophysiological differences between MECP2 ‐allelic disorders

Davut Pehlivan iD, Chengjun Huang, Holly K Harris, Christine Coquery, Aditya Mahat, Mirjana Maletic-Savatic, Laurence Mignon, Sukru Aras, Daniel G Glaze, Charles S Layne, Leonardo Sahelijo, Huda Y Zoghbi und 2 weitere

Annals of Clinical and Translational Neurology · 2025-02 · 12 (2) · 433-447

DOI: 10.1002/acn3.52269 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 21.01.2025. Verfasst von Davut Pehlivan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Section of Pediatric Neurology and Developmental Neuroscience, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, 77030, USA. Hauptthemen laut MEDLINE: Methyl-CpG-Binding Protein 2, Rett Syndrome, X-Linked Intellectual Disability. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Rett Syndrome Research Trust (RSRT), NINDS NIH HHS, Blue Bird Circle Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Rett syndrome (RTT) and MECP2 duplication syndrome (MDS) result from under‐ and overexpression of MECP2 , respectively. Preclinical studies using genetic‐based treatment showed robust phenotype recovery for both MDS and RTT. However, there is a risk of converting MDS to RTT, or vice versa, if accurate MeCP2 levels are not achieved. The aim of this study was to identify biomarkers distinguishing RTT from MDS. Materials and Methods We prospectively enrolled 11 MDS and 6 male RTT like (MRL) individuals for a panel of clinical and neurophysiological assessments over two visits, 8–10 months apart.

Results

We identified numerous clinical and physiological features as promising biomarkers. MRL individuals exhibited large amplitude whole body tremor, midline stereotypies (vs. hand flapping at sides in MDS), earlier neuromotor regression, and earlier onset but less commonly refractory epilepsy. In the neurophysiological domain, we observed several marked differences in sleep physiology between MDS/MRL and typically developing (TD) individuals including reduced sleeping time, increased delta power during rapid eye movement (REM) sleep, decreased occipital alpha and increased brain‐wide delta power during wakefulness, and reduced spindle density and duration. MRL individuals also had much lower delta power during NREM 2 and 3 stages than the TD group. We found differences in spindle duration in the temporal lobes and spindle amplitude in the frontal lobes between MDS and MRL.

Discussion

Our study revealed distinct clinical features of MDS and MRL that can be monitored during a clinical trial and may serve as target engagement, disease progression, or safety biomarkers for interventional studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Methyl-CpG-Binding Protein 2Rett SyndromeX-Linked Intellectual DisabilityHumansMaleChildAdolescentAdultYoung AdultFemaleProspective StudiesElectroencephalographyChild, Preschool

Substanzen

Methyl-CpG-Binding Protein 2MECP2 protein, human

Autor:innen und Institutionen

  • Section of Pediatric Neurology and Developmental Neuroscience, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, 77030, USA.
  • Blue Bird Circle Rett Center, Texas Children's Hospital, Houston, Texas, 77030, USA.
  • Texas Children's Hospital, Houston, Texas, 77030, USA.
  • Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston, Texas, 77030, USA.
  • Section of Developmental Pediatrics, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, 77054, USA.
  • Ionis Pharmaceuticals, Carlsbad, California, 92010, USA.

ORCID-Profile: Davut Pehlivan

Förderung

  • Rett Syndrome Research Trust (RSRT)
  • NINDS NIH HHS
  • Blue Bird Circle Foundation
  • Ionis Pharmaceuticals, Inc.
  • NICHD NIH HHS
  • International Rett Syndrome Foundation
  • Doris Duke Charitable Foundation
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Pehlivan, D., Huang, C., Harris, H. K., Coquery, C., Mahat, A., Maletic-Savatic, M., Mignon, L., Aras, S., Glaze, D. G., Layne, C. S., Sahelijo, L., Zoghbi, H. Y., McGinley, M. J., & Suter, B. (2025). Comprehensive assessment reveals numerous clinical and neurophysiological differences between MECP2 ‐allelic disorders. Annals of Clinical and Translational Neurology, 12(2), 433-447. https://doi.org/10.1002/acn3.52269

Vancouver

Pehlivan D, Huang C, Harris HK, Coquery C, Mahat A, Maletic-Savatic M, et al. Comprehensive assessment reveals numerous clinical and neurophysiological differences between MECP2 ‐allelic disorders. Annals of Clinical and Translational Neurology. 2025;12(2):433-447. doi:10.1002/acn3.52269

BibTeX
@article{Pehlivan2025,
  author = {Pehlivan, Davut and Huang, Chengjun and Harris, Holly K and Coquery, Christine and Mahat, Aditya and Maletic-Savatic, Mirjana and Mignon, Laurence and Aras, Sukru and Glaze, Daniel G and Layne, Charles S and Sahelijo, Leonardo and Zoghbi, Huda Y and McGinley, Matthew J and Suter, Bernhard},
  title = {Comprehensive assessment reveals numerous clinical and neurophysiological differences between MECP2 ‐allelic disorders},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2025},
  volume = {12},
  number = {2},
  pages = {433--447},
  doi = {10.1002/acn3.52269}
}
Kostenlos starten →